Metabolites for the treatment and prevention of autoimmune diseases
Patent Information
- Application Number
- DE602017088571
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-08-10
- Filing Date
- 2017-08-10
- Publication Date
- 2025-03-26
- Estimated Expiration
- 2037-08-10
AI Technical Summary
Current treatments for autoimmune diseases are limited, with no cures available and existing therapies often focusing on managing symptoms rather than addressing the underlying immune response, and are often expensive, making them inaccessible to many patients, particularly for diseases like type 1 diabetes where there are limited treatment options beyond insulin therapy.
A combination of butyric acid and acetic acid, potentially with propionic acid, conjugated to a starch molecule, is delivered to the large intestine, where they can be released as free fatty acids, acting to reduce inflammation and modulate the immune response by increasing anti-inflammatory cytokines and reducing pro-inflammatory cytokines, thereby treating or preventing autoimmune diseases such as type 1 diabetes.
This approach effectively delays or prevents the progression of autoimmune diseases by enhancing gut homeostasis and Treg function, offering a novel treatment modality that is more accessible and cost-effective compared to traditional therapies.